% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Vijayaraghavan:137534,
      author       = {Vijayaraghavan, Swetha and Maetzler, Walter and Reimold,
                      Matthias and Lithner, Christina Unger and Liepelt-Scarfone,
                      Inga and Berg, Daniela and Darreh-Shori, Taher},
      title        = {{H}igh apolipoprotein {E} in cerebrospinal fluid of
                      patients with {L}ewy body disorders is associated with
                      dementia.},
      journal      = {Alzheimer's and dementia},
      volume       = {10},
      number       = {5},
      issn         = {1552-5260},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DZNE-2020-03856},
      pages        = {530-540.e1},
      year         = {2014},
      abstract     = {Apolipoprotein E ε4 allele (APOE ε4) increases the
                      apolipoprotein E (apoE) protein levels in Alzheimer's
                      disease (AD) cerebrospinal fluid (CSF). Thus, we
                      hypothesized that apoE levels were also associated with the
                      APOE genotype, and amyloid-β (Aβ)-associated clinical,
                      functional, and imaging parameters in patients with Lewy
                      body-associated disorders (LBD). Indeed, similar to AD,
                      patients with LBD displayed high CSF apoE levels (greatest
                      in patients with dementia with LBD), and this was linked to
                      APOE ε4. High CSF apoE protein correlated positively with
                      CSF soluble amyloid precursor protein, total tau, and
                      cortical and striatal Pittsburgh compound B retention; and
                      correlated negatively with CSF Aβ42, cognitive tests
                      scores, and glucose uptake ratio in the temporal and
                      parietal cortices. APOE ε4-triggered accumulation of apoE
                      in CSF is related to Aβ-associated clinical and functional
                      imaging parameters in LBD. Accordingly, therapeutic
                      strategies aimed at reducing apoE levels in the brain should
                      be explored not only in AD but also in LBD, particularly
                      when accompanied with dementia.},
      keywords     = {Aged / Aged, 80 and over / Amyloid beta-Peptides:
                      cerebrospinal fluid / Amyloid beta-Protein Precursor:
                      cerebrospinal fluid / Aniline Compounds / Apolipoproteins E:
                      cerebrospinal fluid / Apolipoproteins E: genetics /
                      Biomarkers: cerebrospinal fluid / Brain: diagnostic imaging
                      / Brain: metabolism / Brain: pathology / Carbon
                      Radioisotopes / Cohort Studies / Female / Fluorodeoxyglucose
                      F18 / Glucose: metabolism / Humans / Lewy Body Disease:
                      cerebrospinal fluid / Lewy Body Disease: diagnostic imaging
                      / Lewy Body Disease: genetics / Lewy Body Disease:
                      psychology / Male / Middle Aged / Neuropsychological Tests /
                      Peptide Fragments: cerebrospinal fluid / Positron-Emission
                      Tomography / Radiopharmaceuticals / Thiazoles / tau
                      Proteins: cerebrospinal fluid /
                      2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (NLM
                      Chemicals) / APP protein, human (NLM Chemicals) / Amyloid
                      beta-Peptides (NLM Chemicals) / Amyloid beta-Protein
                      Precursor (NLM Chemicals) / Aniline Compounds (NLM
                      Chemicals) / Apolipoproteins E (NLM Chemicals) / Biomarkers
                      (NLM Chemicals) / Carbon Radioisotopes (NLM Chemicals) /
                      MAPT protein, human (NLM Chemicals) / Peptide Fragments (NLM
                      Chemicals) / Radiopharmaceuticals (NLM Chemicals) /
                      Thiazoles (NLM Chemicals) / amyloid beta-protein (1-42) (NLM
                      Chemicals) / tau Proteins (NLM Chemicals) /
                      Fluorodeoxyglucose F18 (NLM Chemicals) / Glucose (NLM
                      Chemicals)},
      cin          = {AG Maetzler / AG Gasser / AG Berg ; AG Berg},
      ddc          = {610},
      cid          = {I:(DE-2719)5000024 / I:(DE-2719)1210000 /
                      I:(DE-2719)5000055},
      pnm          = {344 - Clinical and Health Care Research (POF3-344) / 345 -
                      Population Studies and Genetics (POF3-345)},
      pid          = {G:(DE-HGF)POF3-344 / G:(DE-HGF)POF3-345},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:23978325},
      doi          = {10.1016/j.jalz.2013.03.010},
      url          = {https://pub.dzne.de/record/137534},
}